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Abstract: A primary pillar of facial rejuvenation is the replacement of soft tissue atrophy via 
a variety of augmentation techniques. The techniques can be classified into three categories, 
skeletal onlay grafts, subcutaneous volumizers, and dermal fillers. While onlay grafts and 
subcutaneous volumizers have the most persistent results, the emergence of improved dermal 
fillers in the past 5 years has become increasingly popular. An accurate diagnosis of the level(s) 
of soft tissue atrophy in the face needs to be made prior to selection of the category or combi-
nation of techniques. In the younger patient, the selection of a dermal filler or combination of 
fillers can be adequate for treatment. A comparison of the composition and characteristics of 
the available dermal fillers are discussed in detail to assist the clinician in understanding the 
actual mechanism of soft tissue augmentation. In the more advanced aging face, a combination 
of the three categories may be necessary to produce optimal results. Just as dermal fillers have 
become more differentiated to increase their longevity, the non-injectible long-lasting implants 
are becoming more developed to mimic accurate viscoelastic properties of the facial soft tissues. 
All three classes of augmentation techniques can provide patients with very satisfactory results 
as part of overall facial rejuvenation.
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As the face ages, wrinkles, grooves, and ptotic tissue become more prominent. 
Superficial wrinkles are largely due to photo damage and resulting solar elastosis. 
This is characterized by loss of collagen mass in the epidermal–dermal junction and 
an increased array of elastin whirls in the deeper dermis. Repeated muscle action 
produces prominent wrinkles and creases in the mimetic areas of facial skin such as 
the glabella, periorbital skin, nasolabial creases, and perioral skin. Grooves appear 
deeper in the nasolabial and marionette zones with the additional feature of fat 
atrophy. As a result of the loss of fat volume, the static suspensory ligaments become 
more lax and the face takes on attributes of ptotic jowls , ptotic malar mounds, and 
nasolabial folds. Skeletal changes resulting in decreased height of the maxilla and 
the mandible occur in the later decades of life (6th–8th decade) and accentuate the 
above findings.
Facial rejuvenation requires an accurate diagnosis of the above findings, and 
therapies are directed at correcting multiple layers. There are four pillars of facial 
rejuvenation: 1) ensuring adequate skeletal framework and support, 2) tightening and 
repositioning of the investing musculofascial aponeurotic system of the face and neck 
(galea, superficial muscular aponeurotic system [SMAS], and platysma), 3) replacement Clinical, Cosmetic and Investigational Dermatology 2009:2 142
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of soft tissue volume loss, and 4) redraping and removal of 
excess skin.
This paper focuses on the third pillar of facial rejuve-
nation and reviews the choices available for soft tissue 
enhancement and replacement. Present-day surgeons have 
a number of choices for facial augmentation which can be 
tailored according to the layer(s) which needs augmentation. 
The options for rejuvenation can be classified as skeletal 
onlay grafts, subcutaneous volume enhancers, and dermal 
fillers. One can also think of the simple classification accord-
ing to depth. The skeletal onlay grafts work from the bone 
upward, the dermal grafts work from the dermis downward, 
and the subcutaneous fillers are in between the two. Dermal 
fillers and subcutaneous volume enhancers have enjoyed the 
greatest degree of development and differentiation because 
they are administered in an office-based setting. Each of the 
three options for volume enhancement will be discussed with 
clinical examples of each.
Skeletal onlay grafts
Skeletal onlay grafts remain one of the most reliable and 
safe options for soft tissue augmentation. Although this is 
an indirect method of soft tissue augmentation, the results 
of enhancing the overlying tissues are indisputable. Much 
experience has been gained from the use of custom carved 
grafts for congenital malar and mandibular hypoplasia and 
the beneficial repositioning of the facial soft tissues that 
brings improved facial harmony. Custom preformed grafts are 
now manufactured from materials such as silastic, expanded 
polytetrafluoroethylene (ePTFE), and Porex.1
These implants require an incision and dissection either 
above or below the periosteum. When the implant is placed, 
it pushes all the overlying soft tissue and skin outward and 
in essence serves as a deep soft tissue filler. These implants 
most commonly involve the chin, mandibular angle, malar 
complex, and nasal dorsum. Skeletal onlay grafts are com-
monly used to address soft tissue volume loss from the 
adipose layers and restore three-dimensional convexity to 
the midface. Examples of onlay grafts enhancing soft tissue 
in the chin and midface are shown in Figure 1.
The placement of skeletal onlay grafts are surgical 
procedures which involve sterile fields and adequate 
knowledge of anatomy to preserve the motor and sensory 
nerves. These implants are typically stabilized with either 
bone fixation or suture/bolster combinations. Patients are 
counseled to expect edema and temporary anesthesia for 
3 weeks and capsule maturation after 6 months. There are 
no clinically significant alterations to bone volume resulting 
A B
Figure 1Before (A) and  after (B) example of soft tissue augmentation with silastic chin onlay graft.Clinical, Cosmetic and Investigational Dermatology 2009:2 143
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in bone loss or soft tissue loss as these implants have been 
in widespread use for the past 30 years. These types of 
soft tissue implants are reversible if there is any need to 
remove them. The most challenging feature of skeletal onlay 
grafting lies not with the technique of placement but in the 
selection of the proper size which matches both the patient 
and physician’s esthetic goals. Fortunately with computer-
aided design, a good selection of three-dimensional shapes 
exist with corresponding sizers which allow for more 
accurate selection.
Further refinements in soft tissue augmentation can 
be made with injectible fillers and/or autogenous fat to 
account for further aging that occurs. Additional dermal 
fillers such as Sculptra® (Sanofi-Aventis, Summit, NJ, 
USA), hyaluronic gels, and Radiesse® (Bioform Medical, 
San Mateo, CA, USA) have been placed over in situ silastic 
implants without complications for the past 3 years. Some 
surgeons prefer exclusive use of autogenous materials for 
augmentation. These grafts can also be custom carved from 
the outer calvarium, ribs, and iliac crest. For smaller onlay 
grafts particularly in the nasal dorsum, septal cartilage, ear 
cartilage, and irradiated rib cartilage are also some options. 
These materials have stood the test of time and are generally 
preferred when alloplastic implants are not practical because 
of concerns about the health of overlying soft tissues. They 
increase the duration of the procedures and have some added 
morbidity because of the need for a donor site. The skeletal 
onlay graft remains the most predictable and permanent 
option for soft tissue enhancement of the face.
Subcutaneous volume enhancers
Autologous fat is the cornerstone of facial volume filling for 
the surgeon in the operating room and should be considered in 
almost every case where generalized soft tissue loss is noted 
in the aging face of immunocompetent patients.2 Success 
with fat grafting still varies among practitioners over the past 
few decades. The key factors which seem to affect overall 
success include harvest methods, placement techniques, 
and choice of recipient site. It is an accepted fact that low 
negative pressure suction with manual syringes offers the 
least traumatic method of fat harvesting. Typically 3-mL to 
10-mL syringes are used with 16-gauge needles or cannulas 
to harvest subcutaneous fat from the abdomen, lateral thighs, 
gluteal areas, or medial knees. Gentle handling of fat with 
some sort of separation from oils and blood can be accom-
plished through gravity decantation or centrifuging. Transfer 
of the harvested fat to 1-mL syringes and blunt cannulas of 
various curves and sizes offers precise placement of small 
0.1-mL aliquots of fat. Using blunt cannulas, low pressure 
and typically depositing on withdrawal of the cannula allow 
for more precise placement of fat pearls at various levels 
including intramuscular levels.
The most common areas of the face which are treated with 
autologous fat grafts include the nasolabial groove, marion-
nete lines, midface, and lips. Autologous fat performs best in 
the midface area considering the longevity compared to other 
more mobile areas such as lips and marionette grooves. Fat 
also remains the filler of choice in combination with aging face 
surgery. These patients are generally in need of more exten-
sive volume replacement and add little additional morbidity 
to the expected bruising and edema typically encountered in 
the postoperative surgical recovery period. The challenging 
areas for successful fat grafting include the nasojugal area and 
lower lid creases. These areas are the most technique depen-
dent for obtaining smooth results and greater complications 
arise with fat grafting in these areas. Strategies to minimize 
complications in these areas include the use of small cannulas 
which allow ultrafine pearls of fat placement and vertical and 
horizonal vector placement paths to avoid clumping.2
There are patients in whom fat grafting is not realistic, 
such as patients with low body fat, eg, long distance runners, 
those in advanced age, and those who have HIV-associated 
lipodystrophy. These patients have been able to withstand large 
volumes and concentrations of synthetic injectible volumizers 
such as calcium hydroxylapatite (Radiesse) and poly-l-lactic 
acid (Sculptra). Both Radiesse and Sculptra are approved in 
the US by the FDA for correction and restoration of facial fat 
loss (lipoatrophy). These patients can take high volumes of 
fillers, typically 3 to 4 times the amount used in the aging-face 
population. These fillers will be discussed in more detail.
Subcutaneous augmentation of the lips is one of the most 
common requests, not only in the aging population but also 
in young adults desiring enhanced lip volume. In addition to 
fat, autologous SMAS fascia has been used to augment sub-
cutaneous tissue in the nasolabial groove and lip with variable 
results.3 There is no filler or implant currently approved by 
the FDA for lip enhancement. The hyalurons are most com-
monly used off-label, with satisfactory but temporary results. 
The difficulty in enhancing the lips relates to the irregular 
nature of the mucous glands in the lips and the temporary 
nature of the hyaluronic gels.
Prior attempts of using alloplastic materials such as 
tubular ePTFE have been suboptimal because of complete 
tissue ingrowth and hardening of some of these implants. 
Improvements in the designs have led to better tolerance 
but have not been able to mimic the softness of hyaluronic Clinical, Cosmetic and Investigational Dermatology 2009:2 144
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gel until the development of saline-filled implants. (Fulfil®; 
Evera Medical, Foster City, CA, USA). The subcutaneous 
lip implantation is done under local anesthesia and it mim-
ics the soft tissue of the lip extremely well.4 The implant 
is composed of a dual-layer membrane which contains the 
saline. These implants are unique because they include a 
dual layer, an inner elastic membrane, and outer microscopic 
ePTFE membrane with a slip plane in between, allowing the 
implant to stretch. By allowing the implant to stretch in vivo, 
this becomes the first alloplastic implant which more closely 
mimics the viscoelastic tissues of the soft tissues of the lips 
and face. These implants are currently being evaluated in a 
controlled FDA trial to assess their cosmetic efficacy for lip 
augmentation. An example of one of the Fulfil implants is 
shown in Figure 2 and a patient example is shown in Figure 3. 
These alloplastic implants offer a potential permanent method 
of subcutaneous augmentation in one of the more challeng-
ing areas of the face. Disadvantages include the fact that the 
procedure comes with a short duration of swelling that the 
patient must plan for and the possible risk of infection with 
an implant.
Dermal fillers
The ideal dermal filler is one that is biocompatible, predictable, 
adjustable to the anatomy of the patient, long-lasting, reversible, 
and natural in appearance. While no single filler possesses all 
of these characteristics, a systematic review will highlight the 
ingredients of each filler and how each one behaves clinically. 
Dermal filler use began in the mid 1980s and has since grown, 
with no fewer than 10 new fillers in the US market. Dermal 
fillers have become the cornerstone of facial filling in the 
office setting. A summary of 12 dermal fillers is shown in 
Table 1 with a simple classification system based on the main 
active component.
Collagen
Bovine collagen was the first filler available and included 
the formulations of Zyderm® and Zyplast® (Allergan, Irvine, 
CA, USA). These products ranged from 35 to 65 mg/mL 
bovine collagen and had 0.3% lidocaine. The cross-linked 
“plast” product was made with glutaraldehyde. A skin test 
was required to screen for the 1.5% to 3% incidence of 
delayed type hypersensitivity. Human collagen equivalents 
in dosing and cross-linking (Cosmoderm® and Cosmoplast®; 
Allergan) were introduced to eliminate the need for allergy 
testing. All of the collagen products have clinical effects 
lasting from 1 to 4 months. The main clinical advantage 
of the human collagen products is their ability to correct 
the most superficial lines with smooth flow characteristics 
as their carrier is phosphate-buffered saline. The duration 
of clinical effects has not been able to reach that of the 
hyaluronic gels as demonstrated in a blinded comparative 
study against Zyplast.5
A porcine-derived collagen (Evolence®; OrthoNeutogena, 
NJ, USA) was given market clearance in 2008 with clinical 
data showing good tolerability without need for a skin 
test. Evolence is composed of 35 mg/mL biodegradable 
type I porcine collagen at a physiologic pH that appears as a 
yellowish opaque gel supplied in a 1-mL syringe and 27-gauge 
needle. Clinical results with porcine collagen show greater 
duration than with the human- or bovine-derived collagens. 
This collagen is highly purified from porcine antigens and 
is cross-linked with D-ribose, making it more resistant to 
degradation. Currently the duration of effect in the nasola-
bial grooves is similar to that of hyaluronic gels. It has very 
smooth flow characteristics through the supplied 27-gauge 
needle, as its carrier is phoshphate-buffered saline.6
Hyaluronans
Hyaluronic acid (HA) is a polysaccharide and a normal 
component of most tissues including dermis. As a result of 
antigenicity and the inconvenience of skin testing for col-
lagen-based fillers, much recent attention has been focused 
on HA. The first HA approved for use in the USA showed 
superior results compared to bovine collagen5 and began a 
wave of HA products for the dermal filler market. HA is 
a ubiquitous component of mammalian connective tissue. 
HA-based polymers offer excellent biocompatibility while 
providing the same structural and mechanical properties of 
Figure 2 Subcutaneous volumizer Fulfil implant prior to placement. Guide needle and 
fill tube shown. Implant is inflated with saline to expand surrounding soft tissue.Clinical, Cosmetic and Investigational Dermatology 2009:2 145
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normal subcutaneous tissue. HA, in its native form has a 
short life span. However, when cross-linked it persists sig-
nificantly longer. Cross-linked hydrogels such as Juvederm® 
(Allergan), Elevess® (Anika Pharmaceutics, Waltham, MA, 
USA), Perlane®, and Restylane® (both Medicis Aesthetics 
Scottsdale, AZ, USA), are among some of the currently 
FDA-approved products used for soft-tissue augmentation. 
All are uniquely cross-linked to give them an in vivo life span 
of 6 to 18 months.
Cross-linked derivatives have been shown to be well 
tolerated when injected into locations such as the skin and vocal 
folds.7 The use of HA is particularly attractive for soft-tissue 
augmentation, because it is hydrophilic and a normal extracel-
lular component of skin. It is directly responsible for much of 
the tissue’s function, and provides little in the way of a host 
immune response since it is conserved across species. Because 
of its tolerability profile, it can be used without skin testing 
and has a life-span that exceeds bovine collagen. In its native 
form, HA is readily metabolized by lymphatic clearance and 
ultimately degraded in the liver to carbon dioxide and water.
Factors that impact HA persistence include HA concen-
tration, percentage of cross-linkage, type of cross-linking, 
its fluid retention (ie, water binding capacity), and injection 
technique. The two most important factors are the percent-
age of cross-linking and the water binding capabilitiy of 
the hyaluronic gel. When uncross-linked HA is added to 
water it produces a highly viscous liquid that would only 
last a few days in human skin.8 To improve the longevity, 
manufacturers use various agents to cross-link the HA. As 
the amount of cross-linking increases, the gel becomes 
more firm and feels more like a solid. As a result, the 
final proportion of cross-linked HA and the degree of 
cross-linking impact the physical characteristic of the final 
product. The water binding capacity or the hydrophilic 
nature allows the HA to create larger volumes relative to 
their mass. Recent studies suggest that increased concentra-
tions of HA prolongs persistence.7 However the concentra-
tion alone is not the most important factor affecting tissue 
persistence but rather the extent of cross-linking of a par-
ticular product. Extent of cross-linking includes the degree 
of cross-linking and the percent of total product which 
is cross-linked. If all other factors were the same among 
HA, the product with the higher degree of cross-linking 
experiences the least amount of degradation by enzymes 
and free radicals.8 Technique can play a role in longevity 
of the dermal filler. Injection into the deep dermis has been 
shown to increase de novo collagen synthesis, hypothesized 
to be the result of fibroblast stretching.9 Therefore as the 
HA is degraded, novel collagen synthesis replaces the HA 
resulting in longer-lasting correction.
One very important characteristic of HA products is the 
ability of clinicians to break down the cross-linking of each 
product with the use of an enzyme known as hyaluronidase. 
This enzyme breaks the cross-links by hydrolysis of the 
glucosamine and glucornic acid moiety. This results in the 
breakage of the cross-links and the three-dimensional structure 
Figure 3 Before (A) and after (B) example of soft tissue augmentation of the lips with the Fulfil implant at 12 months.
A BClinical, Cosmetic and Investigational Dermatology 2009:2 146
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of HA becomes resorbed within hours by the surrounding 
interstitial fluid. Hyaluronidase is available commercially in 
the US as Vitrase® (ISTA Pharmaceuticals) (200 units/mL), 
Amphadase® (Amphastar Pharmaceuticals) (150 units/mL) 
or Hydase® (Prima Pharma) (150 units/mL). One note of 
caution is the possibility of allergic reaction with purified 
bovine testicular hyaluronidase or with preparations that 
contain metabisulfite. A simple skin test can be performed 
by injecting 0.02 mL (3 units) of a 150 unit/mL solution. 
A positive reaction is seen within 5 minutes as a wheal with 
erythema and localized itching. Approximately 15–20 units 
of hyaluronidase can be injected directly into a pea-sized 
volume of HA and cause its dissolution within hours.
Hyaluronic gels with lidocaine
Elevess is an HA produced by Streptococcus equi (bacterial 
fermentation), cross-linked and suspended in a buffer solution 
at a concentration of 28 mg/mL.10 Elevess contains 0.3% lido-
caine HCl and sodium metabisulfite as an antioxidant. A skin 
test is not required. Elevess is a unique hyaluron because of the 
small amount of premixed lidocaine. It is a highly cross-linked 
product which has produced significant swelling in patients 
and requires a 27-gauge needle instead of the the 30-gauge 
needle supplied with the product. This product has not been in 
widespread use and has limited clinical information in the area 
of facial esthetic applications.
Prevelle Silk® (Genzyme Corporation) is another 
hyaluronic acid with 0.3% lidocaine.11 It contains 5.5 mg 
of hyaluronic gel in a 0.75-mL syringe. Due to its low 
concentration and limited cross-linking, it produces minimal 
swelling and also has a shorter duration of effect. It has some 
unique clinical advantages for situations in which a patient 
wants some immediate correction with minimum downtime. 
A good usage of this product is to highlight the vermillion 
border of the lips and to soften vertical perioral lip lines. The 
distribution rights for this product (Mentor Corporation) was 
acquired by Ortho Neutrogena in 2009 which distributes the 
Evolence collagen product for nasolabial grooves.
restylane
Restylane is an HA gel generated by Streptococcus, chemi-
cally cross-linked with 1,4-butanediol diglycidyl ether 
(BDDE), stabilized and suspended in phosphate buffered 
saline at pH 7 and concentration of 20 mg/mL.12 Restylane 
is supplied in a glass syringe with a 30-gauge needle. The 
restylane is 80% cross-linked, with its degree of cross-linking 
approaching 2%. It also has a hardness value of approxi-
mately 400 Pa as compared to Perlane which has a value of 
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approximately 550 Pa when calculated at 5 Hz. It was the first 
stabilized hyaluronic acid dermal filler of nonanimal source 
approved by the FDA in the United States. It has enjoyed 
widespread use in North America with over 1.4 million 
treatments as of 2007, and has an excellent safety profile, 
with skin sensitivity reactions noted in 1:10,000 cases. 
The Restlyane family of products in esthetic soft tissue use 
includes Perlane and Macrolane™ (Q-Med AB). All the 
products are manufactured by Q-med Corporation (Uppsala, 
Sweden) whose products are based on different particle sizes 
which can be filtered into different gels. The different-sized 
gel particles result in different exposures of the product 
to breakdown enzymes and free radicals. The larger-sized 
particles may also be placed deeper in soft tissues. The 
Restylane product contains 100,000 particles per mL, Perlane 
contains 10,000 particles per mL and Macrolane contains 
1000 particles per mL.
Perlane
Perlane is a sterile gel of hyaluronic acid generated by 
Streptococcus species of bacteria, chemically cross-linked 
with BDDE, stabilized, and suspended in phosphate 
buffered saline at pH 7 and a concentration of  20 mg/mL.13 
This product is of the same concentration as Restylane 
and has the same amount and degree of cross-linking as 
Restylane. What makes this product different is the particle 
size which makes Perlane contain about 10,000 particles per 
mL compared to Restylane which has 100,000 particles per 
mL. The largest fraction of gel particle size is between 940 
and 1090 microns. The larger particle of Perlane is thought 
to increase stability of the product by reducing the surface 
area exposed to degradative forces (enzymes and free radi-
cals). Macrolane is a product with even larger particle size 
which is available outside the US for use in body soft tissue 
augmentation.
Juvederm
Juvederm is an HA product derived from bacterial 
(Streptococcus equi) fermentation and has a concentra-
tion of 24 mg/mL.14 It has two different configurations 
in the US (Juvederm Ultra and UltraPlus) and will soon 
have lidocaine incorporated into the product. All the 
Juvederm products contain the same concentration of HA 
and the differentiating factor is the amount of cross-linking 
Figure 4 Before (A) and after (B) example of soft tissue augmentation of the nasolabial grooves with calcium hydroxlyapatite (radiesse) at 6 months.
A BClinical, Cosmetic and Investigational Dermatology 2009:2 148
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in each product. The same cross-linking agent, BDDE, is 
utilized. The Juvederm Ultra product is 90% cross-linked 
with a degree of cross-linking at 6% and comes in a 0.8-mL 
syringe with a 30-gauge needle. Juvederm Ultra has a slightly 
smoother gel consistency compared to Juvederm Ultra Plus 
with a gel hardness measured at approximately 180 Pa. 
The Ultra Plus has gel hardness of 200 Pa and is injected 
with a 27-gauge needle compared to the Ultra product. The 
Ultra Plus has a higher degree of cross-linking of 8% when 
compared to Juvederm Ultra (6%) and explains the longer 
duration of effect compared to the Ultra Juvederm product. 
The Juvederm family of products also seem to have higher 
hydrophilic properties compared to Restylane. The clinical 
significance of this observation has yet to be studied but the 
author’s preference for off-label uses of the hyaluronic gels 
is for the use of Juvederm Ultra Plus for lip enhancement. 
In this location, the greater hydrophilic property plumps the 
lips and gives a softer feel. In the nasojugal area, Restylane 
is preferred because there is less edema and its greater firm-
ness makes it easier to mold and avoid excess swelling for 
patients post-treatment.
Potential complications of HA
HA dermal fillers as a group are very well tolerated. Infection 
can occur but is rare. Hypersensitivity reactions are also 
uncommon, and may result from reaction to the cross-
linking agent used to stabilize the HA. Occasionally HA 
can be palpated, or a blue-gray tinge can be seen in the area 
of injection. This can be the result of superficial injection 
allowing more water binding in the dermis which selectively 
reflects blue wavelength of light making it appear darker 
than the surrounding skin. Solutions to this problem can be 
addressed by camouflage with makeup, needle puncture, 
and massage of excess gel from the dermis or injection of 
hyaluronidase. Injection technique can lead to clumping of 
HA especially in the lips. Massaging the area immediately 
following injection is the best way to prevent lumps from 
persisting. It is important to have patients understand the 
expected clinical course of swelling, firmness, and then 
softening which typically occurs over the course of 1 week. 
One of the benefits of using HA for the less experienced 
user is the fact that they can be readily broken down by the 
hyaluronidase.
Biodegradeable microparticle injectible 
implants
Calcium hydroxylapatite
This particular augmenting agent contains smooth spheres of 
(30%) calcium hydoxylapetite between 25 and 45 microns 
and 70% carboxymethylcellulose gel suspension. This gives 
the product a white color which is then injected subdermally 
typically in a threading technique using a unique 28-gauge 
needle with a foraminal diameter of 27-gauge. This filler is 
also unique in that the standard syringe volume is 1.5 mL of 
material, making it the largest packaged syringe by volume. 
Radiesse has been cleared by the FDA for correction of 
lipoatrophy in persons with human immunodeficiency 
virus.15 In 2006, a cosmetic approval was granted for 
the correction of moderate to severe wrinkles and folds. 
Although it can appear radiopaque in radiographic films, 
there is no indication that it causes masking of abnormal 
tissues.15 It is important to stress that there have been no 
reported cases of granulomas in over 1000 patients treated 
with Radiesse with follow up for 5 years. Its persistence in 
clinical effectiveness is greater when compared to hyaluronic 
gels in the nasolabial grooves, and for many physicians it is 
becoming a first line of choice in soft tissue augmentation.16,17 
Radiesse is not a mucopolysaccharide and therefore does not 
rely on water binding for its persisting clinical effect and it 
does not carry the risk of producing Tyndall effect (blue-gray 
discoloration) in the skin. Because it contains microspheres 
of calcium hydroxylapatite and collagen forms around these 
particles (Figure 5), these physical properties can lead to 
more palpability in the soft subcutaneous tissues of the lips. 
Therefore Radiesse is not recommended for use in the pink 
body of the lips to avoid palpability or nodule formation. 
Treatment of nodules can be reversed by a slit incision and 
surgical removal as they are very well circumscribed and do 
Figure 5 Histologic photomicrograph of calcium hydroxlyapatite with neocollagenesis 
at 16 months in a canine model.Clinical, Cosmetic and Investigational Dermatology 2009:2 149
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not produce significant inflammation beyond their physical 
boundary. It is important to stress that no true granulomas 
have been seen with the use of Radiesse as all of the material 
is biocompatible.
Poly-l-lactic acid (PLLA)
Another  injectible  implant  with  micoparticles  is 
Sculptra. It is supplied as a vial (367.5 mg) of freeze 
dried powder of synthetic L-polymer of polylactic acid 
(which is from the alpha-hydroxy-acid family), sodium 
carboxymethylcellulose, and mannitol. This vial must be 
reconstituted with sterile water at a minimum of 2 hours 
prior to use but in clinical practice is usually done 1 day 
prior to its use.18 Sculptra was approved by the FDA in 
2004 for correction of HIV-related facial atrophy. This 
compound had been known as New-Fill in Europe and has 
been available since 1999. It is currently undergoing review 
for possible esthetic clearance by the FDA. The method of 
volume enhancement with this particular product is thought 
to be due to a controlled inflammation where fibroblasts 
leave collagen as the PLLA is degraded. Clinical results are 
typically seen after 4 to 6 weeks as the immediate swelling 
from the diluent resolves after 48 hours.
The esthetic success with this product in immuno-
competent patients is dependent on dilution volume and 
its correct placement. The original recommended dilution 
volume of 3 mL had a high incidence (30%–52%) of 
subcutaneous nodules which most of the time were palpaple 
but not visible.19 As more volume of diluent (5 mL is now 
the minimum recommended volume per vial) has been 
added, the incidence of nodules has dropped to 6% to 13%.20 
It is also important to allow enough time for the diluents of 
sterile water to adequately hydrate the particles and there-
fore proper planning is required for patient appointments. 
The microparticles of PLLA need to be placed subdermally 
at subcutaneous junction with a minimum of a 26-gauge 
needle to avoid clogging. (Figure 6). One must massage the 
injection sites immediately afterwards and have the patient 
continue to massage for 5 days post-treatment. It is now 
recommended to use 5 to 6 mL of diluents with adequate set 
up time to help diminish the incidence of nodules. Sculptra 
can be delivered through a depot method or a crosshatching 
linear threading technique in the cheeks, temples, and lateral 
face. Sculptra should not be injected in the periorbital area or 
the lips because palpable and visible nodules in these areas 
are difficult to treat. Either technique or combinations has 
given patients persistence of volume that have lasted for up 
to 2 years.20
Non-absorbable fillers
Artefill (poly methylmethacryalate PMMA  
with collagen)
Within the US, there is limited experience with permanent 
fillers. The only FDA approved product is Artefill (Artes 
Medical) which is a combination of bovine collagen and 
particles of polymethylmethacralate (PMMA). PMMA consists 
of non-absorbable microspheres 20 to 50 microns in diameter. 
The carrier gel is composed of 3.5% bovine collagen, 92.6% 
buffered isotonic water, 0.3% lidocaine HCl, 2.7% phosphate 
buffer, and 0.9% sodium chloride which is resorbed over 
2 to 3 months. After resorption of the bovine collagen and 
gel carrier, the resulting PMMA microspheres are surrounded 
by neocollagen. Skin testing is needed for Artefill because of 
the bovine collagen component. This filler is injected with a 
26-gauge needle that is supplied and should not be overcor-
rected. Because of the smooth microspheres and the filtered 
size of PMMA (20–51 microns), with Artefill there was a very 
low incidence of granuloma which plagued earlier formulations 
of other products that contained PMMA.21 Our limited use of 
this product over the past year has yielded good results in the 
marionette area and lateral commissure lines with a series of 
2 to 3 injections over 6 to 8 months. At the end of 2008, Artes 
Medical ceased operations in the US and the fate of this particular 
product remains unclear as of the time of writing this paper.
Silicone
Liquid silicone fine droplet injection is used on a limited basis 
by certain physicians for long-term permanent corrections, 
but with significant risks.22 As this is a permanent material, 
correction of problems usually requires surgical excision. 
The risk of granuloma formation has always existed which 
Figure 6 Illustration showing proper placement of poly-l-lactic acid (Sculptra) in the 
deep dermis/subcutaneous fat.   Top layer = epidermis, Middle layer = dermis, Bottom 
layer in yellow = subcutaneous fat.Clinical, Cosmetic and Investigational Dermatology 2009:2
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has been attributed to a number of factors including purity, 
particle size, and injection technique. There is no approved 
silicone for soft tissue skin augmentation. However, off-label 
uses of ophthalmologic preparations (AdatoSil® 5000 and 
Silikon® 1000) of silicone have been adapted for use in the 
treatment of HIV-associated-lipoatrophy and other clinical 
conditions of facial volume loss. Some studies are underway 
to evaluate Silskin (a liquid silicone similar to Silikon 1000) 
using the microdroplet technique which involves small 
aliquots 0.01 to 0.03 mL spaced at 2 to 10 mm distances in 
the subcutaneous tissues.23 While silicone has great promise 
as a permanent filler, there is much to be analyzed from 
the current and future studies.
Summary
The current options for soft tissue augmentation have 
increased because of the safety and differentiation of the 
injectible products. While skeletal onlay grafts and autolo-
gous fat augmentation have helped surgeons address most 
soft tissue deficiencies, we now see the use of additional 
fillers giving patients and non surgeons options for achieving 
temporary enhancement. The current filler choices can add 
to further soft tissue replacements as patients age with the 
more standard skeletal onlay grafts. The development of the 
saline lip implant serves as an example of how alloplastic 
materials attempt to mimic more the viscoelastic properties 
of natural soft tissue without the need for repeated treatments 
as with temporary fillers. There is no doubt that the use of 
soft tissue fillers will become more widespread as they have 
become well liked by patients and physicians.
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